Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by palinc2000on Sep 19, 2022 5:48pm
137 Views
Post# 34972341

RE:RE:RE:Cantor Conference

RE:RE:RE:Cantor ConferenceI should have added that I am not pleased that we still have the CFO that was there when Paul joined....Makes no sense to me 

palinc2000 wrote: Paul had 3 strikes against him the day he started,,,,-1- The start of a 2 yr pandemic which made it impossible to adress the stagnant sales situation 2-A big dark overhanging  cloud of a stupid Convert which was not of his making 3- A Company  with very little talent and an organizational structure  resembling a corner store...
He has done a hell of a job in rebuilding and I am impressed at his grasp of the business 
So when he joined a 25 old company he was handed  stagnant sales ,no cash . an unproven and still  to this day an unproven  Oncology platform which by the way cost almost zero to purchase from Katana and which Katana had put on the market for over a year with no taker sand very oddly for which the sellers will  ot be getting any royalty payments in future sales which shows how desperate they were to sell. We were told before Paiul joined  that the Nash  ttrial was almost settled pending only harmonization between EMA and FDA....
So he was imo handed a close to a moribond company and unfortunately the pandemic prevented him from proving that he was a marketing ace

Am I pleased with the SP ? No but like they say only in the dictionary does success come before work......Paul has built a great foundation and I am more than willing to give  him more time  do his thing ....AND BTW SICK OF THE NEAR HOURLY REPETIOUS COMMENTS ON THE SP VARIATION....

Bucknelly21 wrote:

I understand the sarcasm, but in two years is this where you thought paul would take us?

 

palinc2000 wrote: Too late for the couple in the midst of a divorce! !!!
Paul should have hired a marriage counsellor to delay the sale of the couples THTX holding
Paul cant do anything right! Lol

 

 





<< Previous
Bullboard Posts
Next >>